Obesity and metabolic syndrome tied to hepatobiliary cancer risk

  • Menon S & al.
  • Indian J Gastroenterol
  • 10 Jan 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Obesity and metabolic syndrome are associated with the risk of developing hepatobiliary cancer.
  • Statin use seems protective against hepatobiliary cancer.

Why this matters

  • The incidence of hepatobiliary cancer has been steadily increasing and there is no clarity if this increase is a consequence of an increase in the prevalence of metabolic syndrome.

Study design

  • This case-control study used data from the Health Improvement Network (THIN) database to investigate the association between obesity/metabolic syndrome and hepatobiliary cancer.
  • 4287 patients (male, 62%; female, 38%) with hepatobiliary cancers were matched with 8574 control patients.
  • Funding: The South Staffordshire Medical Centre Charitable Trust.

Key results

  • On univariate analysis, BMI, diabetes, alcohol consumption, ischaemic heart disease, smoking and hypertension (P<.001 for all were associated with hepatobiliary cancer.>
  • On univariate analysis, statin use (P<.001 and non-smoking status were inversely associated with hepatobiliary cancer.>
  • Multivariate analysis revealed that BMI, hypertension, diabetes, ischaemic heart disease, and insulin use were associated with the risk of developing hepatobiliary cancer.
  • In multivariate analysis, statin use and non-smoking status were inversely associated with hepatobiliary cancer.
  • Increasing BMI, diabetes and hypertension were modelled as a single covariate and were seen to be significantly associated with hepatobiliary cancer (OR, 1.59; 95% CI, 1.49-1.69, P<.001>
  • This association persisted even after adjusting for increasing age (OR, 1.006; 95% CI, 1005-1.006; P<.001 and background liver cirrhosis ci p>

Limitations

  • This study was performed on a database and is subject to the quality of data within the data set.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit